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The overall objectives of this research are to (i) develop azulene-based positron emission
tomography (PET) probes and (ii) image COX2 as a potential biomarker of breast cancer.
Several lines of research have demonstrated that COX2 is overexpressed in breast cancer
and that its presence correlates with poor prognoses. While other studies have reported
that COX2 inhibition can bemodulated and used beneﬁcially as a chemopreventive strategy
in cancer, no viable mechanism for achieving that approach has yet been developed. This
shortfall could be circumvented through in vivo imaging of COX2 activity, particularly using
sensitive imaging techniques such as PET. Toward that goal, our laboratory focuses on the
development of novel 18F-labled COX2 probes. We began the synthesis of the probes by
transforming tropolone into a lactone, which was subjected to an [8 + 2] cycloaddition
reaction to yield 2-methylazulene as the core ring of the probe. After exploring numerous
synthetic routes, the ﬁnal target molecule and precursor PET compounds were prepared
successfully using convergent synthesis. Conventional 18F labeling methods caused pre-
cursor decomposition, which prompted us to hypothesize that the acidic protons of the
methylene moiety between the azulene and thiazole rings were readily abstracted by a
strong base such as potassium carbonate. Ultimately, this caused the precursors to disin-
tegrate. This observation was supported after successfully using an 18F labeling strategy
that employed a much milder phosphate buffer. The 18F-labeled COX2 probe was tested
in a breast cancer xenograft mouse model. The data obtained via successive whole-body
PET/CT scans indicated probe accumulation and retention in the tumor. Overall, the probe
was stable in vivo and no deﬂuorination was observed. A biodistribution study andWestern
blot analysis corroborate with the imaging data. In conclusion, this novel COX2 PET probe
was shown to be a promising agent for cancer imaging and deserves further investigation.
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INTRODUCTION
Prostaglandin endoperoxide synthase, known more commonly as
cyclooxygenase (COX), is the key enzyme required for the con-
version of arachidonic acid to the biological mediators known
as prostanoids, which include prostaglandins, prostacyclin, and
thromboxane (Moore and Simmons, 2000). The two COX iso-
forms,COX1andCOX2, are expressed indifferent tissue at varying
degrees (Dubois et al., 1998).While COX1 is expressed under basal
conditions in almost all tissues and is particularly important to
the maintenance of gastric mucosal integrity, renal function, and
hemostasis, COX2 is undetectable in most normal tissues (van
Ryn et al., 2000). COX2 is highly inducible in cells involved in
inﬂammation and cancer (Rouzer and Marnett, 2009). In addi-
tion to the role it plays in inﬂammation, several lines of research
suggest that COX2 is involved in the early stage of tumorigenesis
(Yokota et al., 1986; Xie et al., 1991). Notably, COX2 not only con-
tinues to express during tumor progress, but the expression of
COX2 also indicates an aggressive tumor phenotype that behaves
more invasively (Fujita et al., 1998) and thus, a poor progno-
sis (Sobolewski et al., 2010). COX2 overexpression has been well
documented in several human carcinomas including colon (Nasir
et al., 2011), stomach (Murata et al., 1999), lung (Hida et al., 1998),
breast (Glynn et al., 2010; Singh et al., 2011), head and neck (Chan
et al., 1998), bladder (Shimada et al., 2011), and pancreas (Hill
et al., 2012).
The relationship between cancers and increased COX2 activity
provides a rationale for the use of COX2 as a prognostic marker
and as a quantiﬁable indicator of tumor progression and treatment
efﬁcacy. Collectively, this approach could be achieved through
in vivo imaging of COX2 activity, especially when using a sensitive
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imaging technique such as positron emission tomography (PET).
A number of research initiatives have reported the development
of COX2 probes with which to visualize cancer-related inﬂam-
mation including its use in optical (Uddin et al., 2010) and PET
imaging (McCarthy et al., 2002; Prabhakaran et al., 2005; Uddin
et al., 2011). Our laboratory has focused on the development
of azulene-based COX2 probes owing to the nanomolar afﬁnity
and high selectivity toward the COX2 enzyme reported previ-
ously (Tomiyama et al., 1999). Azulene has a structural backbone
similar to indomethacin and sulindac, two of the most common
non-steroidal anti-inﬂammatory drugs (NSAIDs). However, the
difference between such NSAIDs and this non-benzenoid aro-
matic hydrocarbon is the existence of a 7-member ring. According
to Tomiyama et al. (1999) azulene is suitable for COX2 devel-
opment since the larger ring ﬁts well within the larger binding
pocket of COX2 compared to COX1, which enhances COX2
selectivity.
Herein, we describe a novel chemistry approach that uses a con-
vergent synthesis methodology to develop azulene-based COX2
PET probes. Of note, we synthesized the main azulene ring using
the procedure we reported previously (Pham et al., 2002; Nolting
et al., 2009). The two other ring structures were assembled onto
the azulene ring using commercially available analogs. To retain
the biological activity as reported by Tomiyama et al. (1999), we
designed the precursors speciﬁcally with 18F ﬂuoride labeling in
mind. Not only do we prefer this isotope due to its relatively long
half-life, but also because replacing a hydrogen atom with a ﬂu-
orine is likely to not affect biological activity since they are very
similar sterically (Jalilian et al., 2000; Mueller et al., 2007). We also
report herein, to our knowledge, the ﬁrst time, a modiﬁed label-
ing condition that uses dipotassium phosphate (K2HPO4) for this
family of compounds, which we found to be unstable using the
conventional PET labeling process. Overall, the chemical yield
of this 7-step synthesis of the nitro precursor 12 (Figure 1) is
25%. The biodistribution results and small animal PET imaging
demonstrate the potential use of the 18F-COX2 probe in breast
cancer imaging.
MATERIALS AND METHODS
CHEMICALS AND CHARACTERIZATION
We synthesized 2-methyl azulene 2 and reported that outcome
in previous publications (Pham et al., 2002; Nolting et al., 2009).
All reagents were obtained through commercial sources such as
Sigma–Aldrich, Acros, or Tokyo Chemical Industry (TCI) and
were used without further puriﬁcation. Solvents were puriﬁed
using the PureSolv MD puriﬁcation system. All reactions were
conducted in argon-ﬂushed, rubber septum-sealed ﬂasks, and the
reagents were introduced via tight-gas syringes. Reaction progress
wasmonitored by thin layer chromatography (TLC) on pre-coated
silica gel plates. Visualization was accomplished by the naked eyes
and by 254 nm-UV light. Flash chromatography separations were
performedusingBiotage andTeledyne systems. HPLCanalysis and
puriﬁcation were performed using diode array Hitachi LaChrome
Elite® systems. 1H NMR and 13C NMR spectra were recorded on
a Bruker 400 MHz spectrometer in CDCl3 using tetramethylsilane
(TMS) as the internal standard. All chemical shifts were reported
in ppm.
2-Methylazulene-1-carbaldehyde (Compound 3)
POCl3 (3.86 mL, 42.2 mmol) was added slowly to a stirring
dimethylformamide (DMF) solution at 0◦C. The mixture was
cooled for 1 h before a DMF solution of 2-methyl azulene (2.0 g,
14.1 mmol) was added drop-wise. The reaction was mixed for 2 h
at 0◦C, and then quenched with cold 10% NaOH. The organic
layer was extracted into ethyl acetate after which the extracts were
washedwithwater andbrine, driedwithMgSO4 andpuriﬁedusing
ﬂash chromatography (ethyl acetate and hexane). The puriﬁed
material was dried down into a dark red solid. Yield: 2.389 g, 89%.
1H NMR (400 MHz, CDCl3) δ 10.50 (s, 1 H), 9.44 (d, J = 9.73 Hz,
1 H), 8.29 (d, J = 9.72 Hz, 1 H), 7.72 (t, J = 9.82 Hz, 1 H), 7.56
(t, J = 9.82 Hz, 1 H), 7.46 (t, J = 9.67 Hz, 1 H), 7.08 (s, 1 H), 2.84
(s, 3 H); 13C NMR (100 MHz, CDCl3) δ 185.8, 154.9, 144.4, 142.1,
137.9, 136.4, 129.7, 128.5, 122.5, 120.3, 15.1. HRMS (ES) calcd.
MH+ (C12H11O) 171.0732 found 171.0804.
(2-Methylazulen-1-yl)(4-methylthiazol-2-yl)methanol (compound 5)
4-Methyl thiazole 4 (837 μL, 9.2 mmol) was added to 20 mL of
tetrahydrofuran (THF). The mixture was cooled to −78◦C and
stirred for 20 min. Afterward, 2.5 M nBuLi (2.45 mL, 6.1 mmol)
was added slowly over the course of 15 min. The resultant mixture
was stirred at −78◦C for 1 h, after which a freshly made solution
of 2-methylazulene-1-carbaldehyde 3 (522 mg, 3.1 mmol) in THF
was added slowly at −78◦C. The reaction was stirred for 30 min
and checked by TLC (50:50 Hexanes/EtOAc). Hexane was added
at −78◦C and the reaction was warmed to room temperature.
Water was added to quench the reaction and the organic layer was
extracted into ethyl acetate. The extracts were washed with water
and brine, dried with MgSO4 and puriﬁed using ﬂash chromatog-
raphy (ethyl acetate and hexane). The puriﬁed material was dried
down into a purple solid. Yield: 768 mg, 93%. 1H NMR (400 MHz,
CDCl3) δ 8.45 (d, J = 9.85Hz, 1H), 8.19 (d, J = 9.54Hz, 1H), 7.52
(t, J = 9.82Hz, 1H), 7.19–7.13 (m, 3H), 6.78 (s, 1H), 6.64 (s, 1H),
2.56 (s, 3 H), 2.42 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 174.2,
152.2, 149.1, 140.6, 137.2, 136.1, 134.8, 132.4, 125.3, 123.8, 123.6,
118.7, 114.1, 67.8, 16.9, 15.6. HRMS (ES) calcd. [M-H2O+H]+
(C16H14NS) 252.0925, found 252.0836.
4-Methyl-2-((2-methylazulen-1-yl)methyl)thiazole (compound 6)
Triethylsilane (178 μL, 1.11 mmol) was added slowly to 2 mL
of triﬂuoroacetic acid (TFA) at room temperature. The mixture
was cooled to 0◦C and mixed for 30 min. A fresh solution of
(2-methylazulen-1-yl)(4-methylthiazol-2-yl)methanol 5 (100 mg,
0.371 mmol) in dichloromethane was then added slowly to the
mixture being stirred at 0◦C. The reaction was kept at 0◦C for
2 h and then warmed to room temperature. Afterward, the mix-
ture was poured into cold 20% KOH to quench the reaction.
The organic layer was extracted into diethyl ether and washed
with water and brine, dried with MgSO4 and puriﬁed using ﬂash
chromatography (ethyl acetate and hexane). The puriﬁed mate-
rial was dried down into a blue solid. Yield: 64.3 mg, 68%.
1H NMR (400 MHz, CDCl3) δ 8.19 (t, J = 10.38 Hz, 2 H), 7.49
(t, J = 9.90 Hz, 1 H), 7.21 (s, 1 H), 7.17–7.10 (m, 2 H), 6.60 (s, 1
H), 4.68 (s, 2 H), 2.60 (s, 3 H), 2.42 (s, 3 H); 13C NMR (100 MHz,
CDCl3) δ 171.8, 152.1, 149.0, 140.1, 137.0, 135.8, 134.4, 131.5,
123.2, 122.7, 117.8, 113.1, 29.3, 17.0, 15.0. HRMS (ES) calcd.
MH+ [C16H16NS]+ 254.0925, found 254.0990.
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FIGURE 1 |The design of a convergent synthesis approach to develop an azulene-based 18F-COX2 probe 13 and its related precursors.
(2-Methyl-3-((4-methylthiazol-2-yl)methyl)azulen-1-yl)
(4-nitrophenyl)methanone(compound 12)
AlCl3(101 mg, 0.757 mmol) was weighed quickly into an argon-
ﬂushed vial. While the vial was being purged with argon,
dichloroethane was added slowly. The ensuing mixture was
syringed quickly into a round-bottom ﬂask and cooled to 0◦C.
A solution of 4-nitro benzoyl chloride (70 mg, 0.377 mmol) in
dichloroethane was added slowly into the suspension of AlCl3 at
0◦C. This mixture was stirred at 0◦C for 30 min after which a fresh
solution of compound 6 (64 mg, 0.253 mmol) in dichloroethane
was added slowly to the reactionmixture being stirred at 0◦C.After
the reaction was stirred at 0◦C for 30 min, it was brought to room
temperature and then stirred for another 30 min. The reaction was
quenched by adding ice-cold water slowly. The organic layer was
extracted into dichloromethane and washed with water and brine,
dried with MgSO4 and puriﬁed using ﬂash chromatography (ethyl
acetate and hexane). The puriﬁed material was dried down into
a brown/orange solid. Yield: 45 mg, 44%. 1H NMR (400 MHz,
CDCl3) δ 8.63 (d, J = 9.84 Hz, 1 H), 8.44 (d, J = 9.89 Hz,
1 H), 8.29 (d, J = 8.82 Hz, 2 H), 7.86 (d, J = 8.81 Hz, 2 H),
7.71 (t, J = 9.82 Hz, 1 H), 7.46 (t, J = 9.72 Hz, 1 H), 7.29
(t, J = 9.93 Hz, 1 H), 6.67 (s, 1 H), 4.70 (s, 2 H), 2.42 (s, 3 H),
2.39 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 192.2, 170.3, 152.3,
150.4, 149.5, 146.3, 141.4, 140.2, 138.2, 135.6, 133.7, 130.2, 127.2,
125.0, 124.3, 123.6, 123.3, 113.2, 29.0, 16.9. HRMS (ES) calcd
MH+ [C23H19N2O3S]+403.1038, found 403.1106.
LABELING SYNTHESIS
No-carrier-added [18F]F− (3.46 Ci) from a cyclotron was iso-
lated from [18O]H2O by trapping it in a small MP1 ﬂuoride trap
and release cartridge that has been conditioned with water and
air-dried. The [18F]F− was then eluted with an acetonitrile/water
mixture containing 20 mg of Kryptoﬁx 222 and 5.0 mg of
dipotassium phosphate trihydrate (K2HPO4.3H2O) into a con-
ically shaped reaction vial previously purged with helium. The
[18F]F−solution was evaporated under a small stream of helium
at 100◦C after which the residue was dried by azeotropic evapo-
ration with anhydrous acetonitrile to ensure anhydrous reaction
conditions were maintained for 18F labeling. After precursors
10 or 12 (2–3 mg, each) were added to the reaction vial, the
resultant mixture was heated to 110◦C for 15 min. After cool-
ing to 30◦C the reaction mixture was diluted with 4.4 mL of
mobile phase (60% EtOH/H2O) and loaded onto a C-18 semi-
preparative column (Macherey-Nagel C-18 250x10mm). The ﬂow
rate was increased from 0 to 6 mL/min over a 3 min time period.
The 6 mL/min ﬂow rate was maintained for 35 min during which
the radioactive product was collected (28–31 min). The contents
corresponding to the radioactive peak were diluted with 100 mL of
distilled water and loaded onto a C-18 Sep-Pak® pre-conditioned
with ethanol and water. The Sep-Pak was eluted by hand with
1 mL of 200 proof ethanol followed by 9 mL of saline. Qualitative
control of the radioactive product was performed using radio-
HPLC (C-18 column, Varian Dynamax, 4.6 × 250 mm, 30–75%
gradient water to acetonitrile over 35 min, ﬂow rate 1 mL/min)
to conﬁrm [18F]ﬂuoride incorporation. The retention time was
compared to that of the “cold” standard compound 11 (retention
time = 20.4 min).
CELL CULTURE AND TUMOR IMPLANTATION
Murine breast cancer cells, C57MG, 4T1, and 67NR were used as
reported previously (Kobukai et al., 2011). Brieﬂy, the cells were
cultured and maintained in Dulbecco modiﬁed Eagle medium
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(Mediatech, Manassas, VA, USA) in the presence of 10% fetal
calf serum (FCS; Invitrogen, Carlesbad, CA, USA), penicillin–
streptomycin antibiotics (Mediatech), and 10 μg/mL insulin
(Sigma–Aldrich, St Louis, MO, USA) at 37◦C and 5% CO2
incubator.
The experimental protocol for animal imaging was approved
by the Vanderbilt Medical Center Institutional Animal Care and
Use Committee. Nude mice 6–8 weeks of age (n = 8, from
Jackson Laboratory, Bar Harbor, ME, USA) were implanted sub-
cutaneously under anesthesia (isoﬂurane mixed with 2% oxygen)
with 1.0 × 106 C57MG cells in the mammary fat pad. The
progress of tumor growthwasmonitored via every-other-daymea-
surement of tumor size and animal weight. When the tumors
reached approximately 4 mm in diameter, in vivo PET imaging
was performed.
IC50 ASSAY
Various concentrations of the 19F-COX2 compound ranging from
0.1 μM to 0.3 nM were dispensed into designated wells within
a 96-well microtiter plate at a ﬁnal volume of 220 μL per well.
Each well contained an assay buffer, heme, and ovine COX2 pro-
vided in Cayman’s colorimetric COX inhibitor screening assay kit.
In addition to the tested probe, the assay condition was accom-
panied by background control wells and the 100% initial activity
wells. Five minutes after incubation of all assay components at
25◦C, an arachidonic acid substrate at a ﬁnal concentration of
100μMand the colorimetric co-substrateN,N,N′,N′-tetramethyl-
p-phenylenediamine were added to each well. The plate was then
incubated at 25◦C for an additional 5 min before reading the
absorbance at 590 nm using a plate reader. Absorbance of the
duplicate assay of each well was averaged and subtracted from
the 100% initial activity sample, after which it was divided by the
100% initial activity sample and multiplied by 100 to arrive at the
percentage of inhibition.
POSITRON EMISSION TOMOGRAPHY
Positron emission tomography imaging was performed using
the microPET Focus 220 (Siemens Pre-clinical, Knoxville, TN,
USA) in a static acquisition mode for 30 min at 60, 120, and
150 min after injection of 18F-COX2 probe 13 (150–200 μCi,
100–130 μL) into awake, non-fasted mice (n = 8) via the tail
vein. To obtain whole-body scans, mice were placed in a supine
position. The data were acquired in a 3-D mode with an axial
span of approximately 8 cm. During the scanning, the ani-
mals were anesthetized using isoﬂurane and the temperature
inside the scanner was maintained at 30◦C using a pad con-
nected to a circulating warm water bath. After PET imaging, a
CT image was acquired using the microCAT II (Siemens Pre-
clinical, Knoxville, TN, USA) using the same animal holder with
the subjects maintained under anesthesia throughout, and then
the mice were immediately euthanized upon completion of the
CT scan. PET images were reconstructed using the iterative MAP
reconstruction algorithm with 18 iterations and a beta smooth-
ing value of 0.001 into 128 × 128 × 95 slices with a voxel size of
0.475 mm × 0.475 mm × 0.796 mm. The PET and CT images
were co-registered using the imaging tool AMIDE (Loening and
Gambhir, 2003).
BIODISTRIBUTION
After the imaging session, the mice were euthanized and hearts,
muscles, blood, livers, spleens, kidneys, stomachs, brains,
intestines, tumors, and lungs were retrieved. The tissues were
weighed and assessed for 18F radioactivity using a gamma counter
(CRC-15W, Capintec, Ramsey, NJ, USA).
WESTERN BLOT
Cells were washed twice with PBS, and lysed in ice-cold lysis buffer
(50 mM Tris–HCl, pH7.4, 0.5% Triton X-100, 0.25% NP-40,
0.25% Na deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA),
supplemented with complete anti-protease cocktail (Sigma). After
removing nuclear and insoluble debris at 16,000g for 20 min,
the supernatant designated as whole cell lysate (WCL) was saved.
Protein concentrations were determined with Bradford method
(Bio-Rad assay, Bio-Rad, Hercules, CA, USA). Thirty micrograms
of WCL proteins were separated by 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
ontopolyvinylidenediﬂuoridemembranes (PVDF,Biorad). Mem-
branes were blocked with 5% dry milk in Tris-buffered Saline
with 0.1% Tween-20 (TBST) and immunoblotted overnight at
4◦C with primary antibodies against COX2. β-Tubulin antibody
(Santa Cruz) was used to blot same membrane for loading con-
trol. After washing with TBST three times, horse radish peroxidase
(HRP) conjugated secondary antibodies were added for 1 h incu-
bation. After washwith TBST twice and oncewith TBS, the protein
bandswere detectedwith an enhanced chemiluminescence (Pierce,
Rockford, IL, USA) by exposure to ﬁlms (Kodak) for 30 s. Band
intensity was quantiﬁed by using NIH Image J software.
REAL-TIME PCR
Total RNA was isolated and puriﬁed from cultured cells by
using the Qiagen RNAeasy kit. RNA (2 mg) was reversibly tran-
scribed by Superscript II (Invitrogen) with oligo-(dT) as primer
to generate single stranded cDNA by following manufacturer
recommended protocols. Quantitation of mRNA (cDNA) lev-
els for COX2 was carried out by real-time PCR using S16P as
internal controls. Real-time PCR primers were designed by web-
based OligoPerfectTM Designer (Invitrogen). The primer pairs
used in PCR are forward 5′-CAGGAGAGAAGGAAATGGC-3′ and
backward 5′-TGAGGAGAACAGATGGGATT-3′ to yield a 184nt
product. Real-time PCR was carried out with the SYBR-green
mixture from Bio-Rad in a ﬁnal volume of 25 μL, with initial
denaturation at 94◦C for 3 min, followed by 45 cycles of denatu-
ration at 94◦C for 10 s, annealing and extension at 65◦C for 1 min.
PCR products were veriﬁed by acrylamide gel electrophoresis,
melting curve analysis.
RESULTS
CHEMICAL SYNTHESIS AND CONFIRMATION OF THE 18F-COX2
PROBE
Starting with tropolone 1, we synthesized three analogs of the
precursor as shown in Figure 1. The advantage of working with
azulene is that the reaction progress can be monitored via color
changes. For example, evidence that compound 2 was converted
to an aldehyde 3 using the Vilsmeier–Haack reaction resulted in a
color change from blue to red. The thiazole ring was incorporated
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onto azulene in two steps. This included a hydrogenolysis reaction
using triethylsilane in the presence of TFA to yield compound 6,
which is blue. Finally, we used Friedel–Crafts acylation to attach
an aromatic ring to position 3 of the azulene. This reaction was
completed using dichloroethane at room temperature for 30 min,
which yielded the ﬁnal product, which is brown. Under reaction
conditions similar to those used with p-nitrobenzoyl chloride, 4-
bromobenzoyl chloride provided an average yield of only 17% for
the resultant Friedel–Crafts acylation product. The seemingly low
yield can be attributed to the weak electron-withdrawing group.
From an electronic perspective, we noted that the ﬂuoro moiety is
a much more favorable alternative than its bromo counterpart, as
the ﬂuoro derivative possesses greater electronegativity and is thus
suitable for generating reactive electrophilic acylium ions. Notably,
it is important to perform the Friedel–Crafts reaction as the last
step since the nitro precursors will be reduced to amino groups
under the reduction conditions. Compounds 10 and 12 were
designed for [18F]ﬂuoride labeling while compound 11 was used
as a control to conﬁrm the radiolabeling product and for speciﬁc
activity analysis. All of the intermediates and products were char-
acterized fully by 1H NMR and 13C NMR and mass spectrometry.
18F-COX2 probe
We found this family of azulene compounds to be unstable under
conventional 18F labeling conditions. After exhaustively analyz-
ing every single reagent, solvent, and temperature involved in
the labeling experiment, which included Kryptoﬁx, Dimethyl sul-
foxide (DMSO), DMF, acetonitrile, and potassium carbonate, we
found by HPLC analysis that potassium carbonate was decompos-
ing precursors 10 and 12 instantaneously at room temperature.
This undesired chemical transformationwas easily visualized since
the color changed from brown to black when the precursors came
into contact with potassium carbonate. Although we did not ana-
lyze the intermediates, this undesired reaction could be attributed
to the acidic methylene protons between the azulene and thiazole
ring, which may be sensitive to potassium carbonate. To overcome
this problem,wedecided touse amilder buffer such as dipotassium
phosphate, which works perfectly for this purpose.
Although there was no sign of decomposition after we opti-
mized the labeling conditions, the labeling of the bromo precursor
10 was sluggish. In contrast, we labeled successfully the nitro
derivative 12, albeit with low yield (3%, decay corrected) at
EOS with >99% chemical and radiochemical purities and with
a speciﬁc activity of 733 Ci/mmol.
THE SPECIFICITY OF THE 19F-COX2 COMPOUND FOR THE COX2
ENZYME
In addition to being synthesized for use in facilitating the con-
ﬁrmation of the 18F-labeled product, the cold compound 11 was
also used to assess the IC50 value. The assay was performed using
10 duplicate concentrations in a range comparable to DuP697,
a known COX2 inhibitor. As shown in Figure 2, the Hill slopes
of the curves that represent 19F-COX2 and DuP697 are −0.62
and −1.0, respectively; suggesting the speciﬁcity of the synthe-
sized PET probe for COX2. After taking the background signal
into account, the IC50 value of the 19F-COX2 compound was
661 nM.
FIGURE 2 | 19F-COX2 probe IC50 value determination using a
colorimetric assay against DuP697, a known COX2 inhibitor in a
96-well plate format. Data represent two independent experiments.
COX2 IS OVEREXPRESSED IN C57MG BREAST CANCER CELLS
To conﬁrm and quantify COX2 expression in the C57MG cell
line, we selected two other cells, 4T1 and 67NR, which are also
murine breast cancer cell lines. It has been demonstrated previ-
ously that the 4T1 (Harmey et al., 2002) and 67NR cells (Nagler
et al., 2011) were positive and negative, respectively, for COX2.
As shown in Figure 3, Western blot analysis on cell lysate indi-
cated a very low level of COX2 in 67NR cells. In contrast, C57MG
possesses a high constitutive level of COX2. Furthermore, real-
time PCR data demonstrated that COX2 was expressed at a
rate approximately 31-fold higher in C57MG cells compared to
67NR.
IN VIVO IMAGING OF COX2 IN TUMOR MOUSE MODEL AND
BIODISTRIBUTION
To assess the speciﬁcity of the probes for the detection of COX2
expression, we performed in vivo PET imaging of non-fasted
mice in which C57MG tumors had been implanted on the mam-
mary fat pads. We monitored the distribution of the probe in
breast cancer at several times after the intravenous bolus injection.
The optimal emission data were collected during a static, whole-
body scan 150 min after administration of the probe. PET and
PET/CT images showed accumulation and retention of the 18F-
COX2 probe 13 and that signiﬁcant accumulation in the tumor
resulted in high signal intensity compared to the background
(p < 0.05; Figure 4). The PET data corroborates withWestern blot
and RT-PCR analysis. We also observed a predominant hepatic
uptake of the probe. That outcome is reasonably understandable
since lipophilic compounds tend to possess a strong afﬁnity for
the liver. In addition, the high liver-bowel activity observed in
this study suggests the possibility of hepatobiliary excretion. The
probe exhibited negligible signal in the bone, thus eliminating the
notion of in vivodeﬂuorination. Figure 5 shows the probe’s biodis-
tribution in non-fasted tumor-bearing mice (n = 3) at 150 min
post injection. The data shows that the probe accumulated in
the tumor; however, the highest uptake was detected in the liver,
followed by the intestine. It is very likely that the high activity
observed in the intestine can be attributed partially to the stool
residuals.
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FIGURE 3 | Analysis of COX2 expression and quantity in murine breast cancer cells.Western blot analysis was performed to verify the presence and
relative intensity of COX2 in C57GM cells compared to other cells. β-actin served as a loading control (left). RT-PCR data were used to quantify the level of
COX2 expression after normalization.
FIGURE 4 | In vivo microPET imaging of COX2 in a tumor-bearing mouse model. At the time of imaging, tumor size was approximately 4 mm in diameter
(*, tumor) (A). Representative PET image of an axial section showing tumor uptake of 18F-COX2 probe (white circle) (B). Fused PET/CT axial image (C). Fused
PET/CT sagittal view of the tumor (D).
STATISTICS
Student’s t-test was used to evaluate statistical differences between
samples. Signiﬁcant differences were considered as p < 0.05.
DISCUSSION
The goal of this work is to design, synthesize and test a novel
class of azulene-based probes with which to image COX2 in
cancer. Although synthesis of this class of COX2 inhibitors has
been reported in the past (Tomiyama et al., 1999), conversion
from an inhibitor to a contrast agent requires an entirely dif-
ferent chemistry. This is because the chemistry used originally
is unsuitable for producing the nitro precursor 12. Conversion
of a nitrile derivative into thioamide using hydrogen sulﬁde,
shown by Tomiyama et al. (1999), concomitantly reduces the
nitro to an amine. Another disadvantage of constructing the
thioamidedirectly from the azulene ring is that theprocess requires
many steps of synthesis, and failure in any single step in the
link will affect the whole scheme. In this project, we utilized
a convergent synthesis strategy wherein the three major rings
of the compound were either synthesized or acquired from a
diverse library of analogs commercially. These were then assem-
bled into the desired product using simple chemistry. Thanks to
this approach, we shortened the synthesis by three or four steps. In
addition, the approach enables the potential generation of a library
of compounds with novel functional groups that offer untapped
bioisosteres.
Another innovative approach of this work lies in the 18F label-
ing process. To our knowledge, currently, there are no reported
data showing an alternative buffer to the conventional use of
potassium carbonate. We hypothesized that the role played by
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FIGURE 5 | Uptake (% injection dose/g tissue) of the 18F-COX2 probe 13 in non-fasted tumor-bearing mice (n = 3).
potassium is that of serving as a counter-ion for the [18F]ﬂuoride
and as such it can be displaced by a similar cation. However, for
these precursors or any basic sensitive compounds, weaker bases
such as dipotassium phosphate should be used as an alternative
since their pH is nearly neutral. Since we have not performed
this sort of experiment on other types of compounds, we cannot
extrapolate the reason why the speciﬁc activity of ﬁnal product is
low. More work is under progress to improve the speciﬁc activ-
ity of compound 13. One approach in that direction is to use
high-grade dipotassium phosphate to ensure the elimination of
trace ﬂuoride in the labeling process. Nevertheless, in view of our
recent ﬁndings and in light of the high number of basic sensitive
precursors that failed in PET labeling, it is appropriate to hope
that this ﬁnding can provide far-reaching applications for other
compounds.
In vivo PET imaging demonstrated that there was no deﬂu-
orination of the probe in vivo even 2.5 h post injection of the
radioligand. To our knowledge, this is the ﬁrst COX2 PET radi-
oligand demonstrating such high stability in vivo. However, as
the scope of this article was to report the chemical development
of the probe, future studies will be needed to fully character-
ize this radioligand in vivo which include blood sampling and
kinetic modeling as well as displacement studies. In addition,
other important issues still need further evaluation. For exam-
ple, we do not have information regarding tumor uptake between
fasted and non-fasted mice. Although there is no systematic or
mechanism that explains the difference between these two groups
of study, Fueger et al. (2006) reported that in fasted mice, tumor
uptake increased fourfold while tumor-to-organ ratios increased
up to 17-fold compared to the non-fasted counterparts. Currently,
work is in progress in our group to address this issue. Further-
more, in vivo blocking studies using cold compound 11 or COX2
inhibitors would be ideal to further conﬁrm the speciﬁcity of this
PET probe.
Data obtained in this work suggest that this probe not only
has the potential to detect inﬂammation, but it can also be used to
detect the early onset of cancer. Furthermore, this targeted imaging
approach is applicable for the assessment of tumor response dur-
ing chemotherapy. Another application for the in vivo imaging of
COX2 lies in cell therapy. Muthuswamy et al. (2010) showed that
COX2 impairs the ability of dendritic cells (DCs) to attract naïve
T cells. One of the mechanisms involved is that COX2 inhibits the
ability of DCs to produce CCL19. In another study, Harizi et al.
(2002) showed that COX2 induced PGE2 enhances the produc-
tion of endogenous IL-10, which downregulates DC functions. By
using COX2 inhibitors to attenuate the expression of IL-10 and
the concomitant restoration of IL-12 production by DCs, Stolina
et al. (2000) demonstrated that the COX2 inhibitor can modulate
and be used beneﬁcially as an adjuvant strategy in cancer therapy.
Altogether, we believe that non-invasive imaging of COX2 with
this probe in breast cancer would provide valuable insight into the
tumor microenvironment.
In conclusion, we have demonstrated an innovative synthetic
approach to the development of a novel class of 18F-COX2 contrast
agents. In addition, we reported on the optimized labeling condi-
tions that can be applied to any base-sensitive PET precursors. The
chemistry we utilized is reproducible and scalable, and each step of
the syntheses described in this work has been repeated and charac-
terized more than 30 times by NMR and mass spectrometry. Most
importantly, small animal PET imaging data suggest the speciﬁcity
of the probe for COX2. In general, it seems reasonably certain that
this class of azulene-based agents deserves further evaluation, as
in vivo imaging of COX2 will offer signiﬁcant insights into the
implication of this enzyme in the inﬂammation–dysplasia–cancer
matrix.
ACKNOWLEDGMENTS
We thank Meiying Zhu and Breia Jefferson for contribut-
ing their effort in the project. This work was supported
by NIH K01AG026366 (Pham), R01CA160700 (Pham), The
VICC Cancer Center Support Grant (Pham) and P50CA128323
(Gore).
www.frontiersin.org January 2013 | Volume 2 | Article 207 | 7
“fonc-02-00207” — 2012/12/31 — 20:43 — page 8 — #8
Nolting et al. COX2 PET probes for cancer imaging
REFERENCES
Chan, T. A., Morin, P. J., Vogel-
stein, B., and Kinzler, K. W.
(1998). Mechanisms underlying non-
steroidal antiinﬂammatory drug-
mediated apoptosis. Proc. Natl. Acad.
Sci. U.S.A. 95, 681–686.
Dubois, R. N., Abramson, S. B., Crof-
ford, L., Gupta, R. A., Simon, L. S.,
Van De Putte, L. B., et al. (1998).
Cyclooxygenase in biology, and dis-
ease. FASEB J. 12, 1063–1073.
Fueger, B. J., Czernin, J., Hildebrandt,
I., Tran, C., Halpern, B. S., Stout,
D., et al. (2006). Impact of animal
handling on the results of 18F-FDG
PET studies in mice. J. Nucl. Med. 47,
999–1006.
Fujita, T., Matsui, M., Takaku, K.,
Uetake, H., Ichikawa, W., Taketo, M.
M., et al. (1998). Size-, and invasion-
dependent increase in cyclooxyge-
nase 2 levels in human colorectal
carcinomas. Cancer Res. 58, 4823–
4826.
Glynn, S. A., Prueitt, R. L., Ridnour,
L. A., Boersma, B. J., Dorsey, T. M.,
Wink, D. A., et al. (2010). COX-
2 activation is associated with Akt
phosphorylation and poor survival
in ER-negative, HER2-positive breast
cancer. BMC Cancer 10:626. doi:
10.1186/1471-2407-10-626
Harizi, H., Juzan, M., Pitard,
V., Moreau, J. F., and Gualde,
N. (2002). Cyclooxygenase-2-issued
prostaglandin e(2) enhances the pro-
duction of endogenous IL-10, which
down-regulates dendritic cell func-
tions. J. Immunol. 168, 2255–
2263.
Harmey, J. H., Bucana, C. D., Lu, W.,
Byrne, A. M., McDonnell, S., Lynch,
C., et al. (2002). Lipopolysaccharide-
induced metastatic growth is asso-
ciated with increased angiogenesis,
vascular permeability and tumor
cell invasion. Int. J. Cancer 101,
415–422.
Hida, T., Yatabe, Y., Achiwa, H., Mura-
matsu, H., Kozaki, K., Nakamura,
S., et al. (1998). Increased expression
of cyclooxygenase 2 occurs frequently
in human lung cancers, speciﬁcally
in adenocarcinomas. Cancer Res. 58,
3761–3764.
Hill, R., Li, Y., Tran, L. M., Dry, S.,
Calvopina, J. H., Garcia, A., et al.
(2012). Cell intrinsic role of Cox-2 in
pancreatic cancer development. Mol.
Cancer Ther. doi: 10.1158/1535-7163
[Epub ahead of print].
Jalilian, A. R., Tabatabai, S. A., Shaﬁee,
A., Afarideh, H., Najaﬁ, R., and
Bineshmarvasti, M. (2000). One-
step, no-carrier-added synthesis of
a 18F-labeled benzodiazepine recep-
tor ligand. J. Labelled Comp. Radio-
pharm. 43, 545–555.
Kobukai, S., Kremers, G. J., Cobb, J.
G., Baheza, R., Xie, J., Kuley, A.,
et al. (2011). Induction of antitumor
immunity by dendritic cells loaded
with MPA11P-conjugated mucin-1
peptide antigen. Transl. Oncol. 4, 1–8.
Loening, A. M., and Gambhir, S.
S. (2003). AMIDE: a free soft-
ware tool for multimodality medi-
cal image analysis. Mol. Imaging 2,
131–137.
McCarthy, T. J., Sheriff, A. U., Graneto,
M. J., Talley, J. J., and Welch, M.
J. (2002). Radiosynthesis, in vitro
validation, and in vivo evaluation
of 18F-labeled COX-1 and COX-2
inhibitors. J. Nucl. Med. 43, 117–124.
Moore, B. C., and Simmons, D. L.
(2000). COX-2 Inhibition, apopto-
sis„ and chemoprevention by non-
steroidal anti-inﬂammatory drugs.
Curr. Med. Chem. 7, 1131–
1144.
Mueller, K., Faeh, C., and Diederich, F.
(2007). Fluorine in pharmaceuticals:
looking beyond intuition. Science
317, 1881–1886.
Murata, H., Kawano, S., Tsuji, S.,
Tsuji, M., Sawaoka, H., Kimura, Y.,
et al. (1999). Cyclooxygenase-2 over-
expression enhances lymphatic inva-
sion and metastasis in human gastric
carcinoma. Am. J. Gastroenterol. 94,
451–455.
Muthuswamy, R., Mueller-Berghaus,
J., Haberkorn, U., Reinhart, T. A.,
Schadendorf, D., and Kalinski, P.
(2010). PGE(2) transiently enhances
DC expression of CCR7 but inhibits
the ability of DCs to produce CCL19
and attract naive T cells. Blood 116,
1454–1459.
Nagler, C., Hardt, C., Zanker, K. S., and
Dittmar, T. (2011). Co-cultivation of
murine BMDCs with 67NR mouse
mammary carcinoma cells give rise to
highly drug resistant cells. Cancer Cell
Int. 11, 21.
Nasir, A., Lopez, A., Boulware, D.,
Malafa, M., and Coppola, D. (2011).
Correlation between COX-2, and
APC expression in left versus right-
sidedhuman colon cancer.Anticancer
Res. 31, 2191–2195.
Nolting, D. D., Nickels, M., Price, R.,
Gore, J. C., and Pham, W. (2009).
Synthesis of bicyclo[5.3.0]azulene
derivatives. Nat. Protoc. 4, 1113–
1117.
Pham, W., Weissleder, R., and Tung,
C. H. (2002). An azulene dimer
as a near-infrared quencher. Angew.
Chem. Int. Ed. Engl. 41, 3659–3662,
3519.
Prabhakaran, J., Majo, V. J., Simpson,
N. R., van Heertum, R. L., Mann, J.
J., and Kumar, J. S. (2005). Synthe-
sis of [11C]celecoxib: a potential PET
probe for imaging COX-2 expression.
J. Labelled Comp. Radiopharm. 48,
887–895.
Rouzer, C. A., and Marnett, L. J.
(2009). Cyclooxygenases: structural,
and functional insights. J. Lipid Res.
50(Suppl.), S29–S34.
Shimada, K., Anai, S., Marco, D.
A., Fujimoto, K., and Konishi, N.
(2011). Cyclooxygenase 2-dependent
and independent activation of Akt
through casein kinase 2alpha con-
tributes to human bladder cancer
cell survival. BMC Urol. 11:8. doi:
10.1186/1471-2490-11-8
Singh, B., Cook, K. R., Vincent, L.,
Hall, C. S., Martin, C., and Lucci, A.
(2011). Role of COX-2 in tumoro-
spheres derived from a breast cancer
cell line. J. Surg. Res. 168, e39–e49.
Sobolewski, C., Cerella, C., Dicato,
M., Ghibelli, L., and Diederich, M.
(2010). The role of cyclooxygenase-2
in cell proliferation and cell death in
human malignancies. Int. J. Cell Biol.
215158.
Stolina, M., Sharma, S., Lin, Y.,
Dohadwala, M., Gardner, B., Luo,
J., et al. (2000). Speciﬁc inhibition
of cyclooxygenase 2 restores antitu-
mor reactivity by altering the bal-
ance of IL-10 and IL-12 synthesis. J.
Immunol. 164, 361–370.
Tomiyama, T., Tomiyama, I., and
Yokota, M. (1999). Preparation
of azulene derivatives as COX-2
inhibitors. JP 11302266:JP 1998-
115303.
Uddin, M. J., Crews, B. C., Blobaum,
A. L., Kingsley, P. J., Gorden, D. L.,
McIntyre, J. O., et al. (2010). Selective
visualization of cyclooxygenase-2 in
inﬂammation and cancer by targeted
ﬂuorescent imaging agents. Cancer
Res. 70, 3618–3627.
Uddin, M. J., Crews, B. C., Ghebre-
selasie, K., Huda, I., Kingsley, P. J.,
Ansari, M. S., et al. (2011). Fluori-
nated cyclooxygnase-2 inhibitors as
agents in PET imaging of inﬂamma-
tion and cancer. Cancer Prev. Res. 4,
1536–1545.
van Ryn, J., Trummlitz, G., and Pairet,
M. (2000). COX-2 selectivity, and
inﬂammatory processes. Curr. Med.
Chem. 7, 1145–1161.
Xie, W. L., Chipman, J. G., Robert-
son, D. L., Erikson, R. L., and Sim-
mons, D. L. (1991). Expression of
a mitogen-responsive gene encoding
prostaglandin synthase is regulated
by mRNA splicing. Proc. Natl. Acad.
Sci. U.S.A. 88, 2692–2696.
Yokota, K., Kusaka, M., Ohshima, T.,
Yamamoto, S., Kurihara, N., Yoshino,
T., et al. (1986). Stimulation of
prostaglandin E2 synthesis in cloned
osteoblastic cells of mouse (MC3T3-
E1) by epidermal growth factor. J.
Biol. Chem. 26115410–15415.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 23 August 2012; accepted: 13
December 2012; published online: 03
January 2013.
Citation: Nolting DD, Nickels M,
Tantawy MN,Yu JYH, Xie J, Peterson TE,
Crews BC, Marnett L, Gore JC and Pham
W (2013) Convergent synthesis and eval-
uation of 18F-labeled azulenic COX2
probes for cancer imaging. Front. Oncol.
2:207. doi: 10.3389/fonc.2012.00207
This article was submitted to Frontiers
in Cancer Imaging and Diagnosis, a
specialty of Frontiers in Oncology.
Copyright © 2013 Nolting, Nickels,
Tantawy, Yu, Xie, Peterson, Crews,
Marnett, Gore and Pham. This is an
open-access article distributed under
the terms of the Creative Commons
Attribution License, which permits use,
distribution and reproduction in other
forums, provided the original authors
and source are credited and subject to
any copyright notices concerning any
third-party graphics etc.
Frontiers in Oncology | Cancer Imaging and Diagnosis January 2013 | Volume 2 | Article 207 | 8
